Krystal Biotech Q4 revenue rises 17.5% driven by VYJUVEK

Krystal Biotech

17/02/2026 12:11

Overview

Biotech firm's Q4 product revenue rose to $107.1 mln, driven by VYJUVEK sales

Net income for Q4 increased to $51.4 mln

Company maintains strong cash position with $955.9 mln in cash and investments

Outlook

Krystal Biotech expects VYJUVEK launch in Italy in 2H 2026

Company plans to expand distributor network to over 40 countries by end of 2026

Krystal Biotech projects FY 2026 non-GAAP R&D and SG&A expenses at $175 mln-$195 mln

Result Drivers

VYJUVEK SALES - Strong demand for VYJUVEK in the U.S. and international markets drove Q4 revenue to $107.1 mln

EUROPEAN PRICING DISCUSSIONS - Ongoing pricing negotiations in Germany and France expected to continue into 2026 and 2027, respectively

CYSTIC FIBROSIS PROGRAM - Positive clinical update from Phase 1 study of KB407 for cystic fibrosis, confirming lung delivery and expression of CFTR protein

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Product Revenue
$107.11 mln
Q4 Net Income
$51.40 mln
Q4 Operating Expenses
$62.84 mln
Q4 Operating Income
$44.27 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Krystal Biotech Inc is $308.00, about 11.4% above its February 13 closing price of $276.45

The stock recently traded at 34 times the next 12-month earnings vs. a P/E of 28 three months ago

Press Release: ID:nGNX6YF4TW

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)